[HTML][HTML] FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
C Antoniotti, MM Germani, D Rossini, S Lonardi… - European Journal of …, 2022 - Elsevier
Background We performed a pooled analysis of TRIBE and TRIBE2 studies to assess the
efficacy and safety of the intensification of upfront chemotherapy backbone–from doublets to …
efficacy and safety of the intensification of upfront chemotherapy backbone–from doublets to …
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and …
C Cremolini, F Loupakis, C Antoniotti, C Lupi… - The Lancet …, 2015 - thelancet.com
Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final …
F Loupakis, C Cremolini, C Antoniotti, S Lonardi… - 2015 - ascopubs.org
3510 Background: The phase III TRIBE study met its primary endpoint by demonstrating that
first-line FOLFOXIRI plus bev significantly prolongs PFS, as compared to FOLFIRI plus bev …
first-line FOLFOXIRI plus bev significantly prolongs PFS, as compared to FOLFIRI plus bev …
[HTML][HTML] Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by …
Background FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and
efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises …
efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises …
[HTML][HTML] FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized …
C Cremolini, F Loupakis, G Masi, S Lonardi… - Annals of …, 2016 - Elsevier
Background FOLFOXIRI plus bevacizumab is a valid option as upfront treatment for
metastatic colorectal cancer (mCRC) patients. While several trials investigated the effect of …
metastatic colorectal cancer (mCRC) patients. While several trials investigated the effect of …
[HTML][HTML] Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and …
F Marmorino, D Rossini, S Lonardi, R Moretto… - Annals of …, 2019 - Elsevier
Abstract Background The phase III TRIBE and TRIBE2 studies randomized metastatic
colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or …
colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or …
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the …
C Cremolini, C Antoniotti, D Rossini, S Lonardi… - The Lancet …, 2020 - thelancet.com
Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …
[HTML][HTML] A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
K Shinozaki, T Yamada, J Nasu, T Matsumoto… - International Journal of …, 2021 - Springer
Purpose FOLFOXIRI plus bevacizumab is regarded as a first-line therapeutic option for
selected patients with metastatic colorectal cancer (mCRC). Our aim was to assess the …
selected patients with metastatic colorectal cancer (mCRC). Our aim was to assess the …
Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal …
C Cremolini, C Antoniotti, A Stein, J Bendell… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE A proper estimation of the magnitude of the overall survival (OS) benefit from
infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus …
infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus …
[HTML][HTML] A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study
E Oki, T Kato, H Bando, T Yoshino, K Muro… - Clinical colorectal …, 2018 - Elsevier
Background FOLFOXIRI (Fluorouracil, folinate, oxaliplatin, and irinotecan) plus
bevacizumab improved progression-free survival (PFS) and overall survival in patients with …
bevacizumab improved progression-free survival (PFS) and overall survival in patients with …